Immunological and Clinical Effect of Long-Term Oral Treatment with RU 41740 in Patients with Chronic Bronchitis: Double-Blind Trial Long-Term versus Standard Dose Regimen
Platelets play an important role in thromboembo lie episodes in the life of patients with heart prosthetic valves. Decreased platelet survival and increased B-Tromboglobulin and Platelet F4 in the blood are constant features of such condition.45 patients on long term anticoagulant treatment (thrombotest 5-10%),26 males(mean age 46) and 19 females(mean age 44), were studied. 22 normal sub jects served as controls.Platelets survival was studied with MDA production after 5oo mg Aspirin intake and was found signifi canly reduced in patients in comparison to contro Is(p.8.00±1.4 days;c.10.00±1.67 days; P<0.01).BTG and PF4 as measured by RIA were increased (BTG:p.97.8±59 NG/ML;c.29.18±22.40 NG/ML; P<0.01) (PF4:p.36.6±26.5 NG/ML;c.6.29±4.78 NG/ML; P<0.01) The patients were randomly allocated to one of the following groups( 15 subjects each): placebo, Suloctidil 600 mg:die, Suloctidil 1200 mg:die. Duration treatment was 30 days.The effect of Suloctidil was significantly different from that of placebo( P<0.005),as regards Platelet survival without difference between dosa ges of the drug;as concerns BTG and PF4 the chang es under placebo and drug were not different.
The therapeutic effect of lithium in mania was first described by Cade (1949), but the possibility that lithium could have a prophylactic action in recurrent affective disorders was not suggested until some years later (Hartigan, 1963; Baastrup, 1964). The early studies of the prophylactic action of lithium were open trials, in which both investigator and patient knew that the patient was receiving the drug. More recently, controlled double-blind studies have confirmed these early reports (Melia, 1970; Coppenet al., 1971; Cundallet al., 19712).
Inhaled GM-CSF (Molgramostim) Therapy Reduces the Need for Whole Lung Lavage in Patients with Autoimmune Pulmonary Alveolar Proteinosis - Long-Term Results from a Randomized, Double-Blind Trial (IMPALA)